Jean Francois Formela, serving as a director at Korro Bio, Inc. (NASDAQ:KRRO), has completed the sale of common stock valued at approximately $2.46 million. According to a recent filing with the Securities and Exchange Commission (SEC), the transactions unfolded over three consecutive trading days: June 22, 23, and 24, 2026. The total volume of the disposition amounted to 171,405 shares of Korro Bio common stock.
The shares were sold at prices that ranged between $13.95 and $14.98 per share. At the time of reporting, the stock was trading at $13.79, a figure that sits near the lower boundary of the recent sale range. Analysis from InvestingPro suggests that the shares are currently fairly valued at these levels. Despite this, the company's stock has experienced strong returns recently, climbing 64% over the past six months. However, InvestingPro Tips indicate that price movements remain highly volatile. Investors seeking further insight can access 10 additional ProTips and comprehensive financial metrics on the platform.
These sales were executed under a Rule 10b5-1 trading plan, which Mr. Formela adopted on April 8, 2026. The shares sold were held indirectly by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P. Mr. Formela, who is a member of the general partners for these funds, has disclaimed beneficial ownership of these shares except to the extent of his pecuniary interest.
In other recent developments, Korro Bio Inc. has announced the addition of KRRO-111 to its development pipeline. This new candidate targets alpha-1 antitrypsin deficiency (AATD). It is a GalNAc-conjugated oligonucleotide designed for subcutaneous delivery to liver cells, with the aim of repairing a pathogenic variant on AAT mRNA. Additionally, Korro Bio’s lead program, KRRO-121, for hyperammonemia in urea cycle disorders and hepatic encephalopathy, remains on schedule for a regulatory filing in the latter half of 2026.
Regarding stock evaluations, Jones Trading has upgraded Korro Bio’s stock rating from Hold to Buy, setting a price target of $23.00. This upgrade is attributed to the promising potential of the company’s AATD program, especially with new preclinical data showing significant improvements in RNA editing. Meanwhile, H.C. Wainwright has lowered its price target for Korro Bio from $20 to $15 but maintained a Buy rating, citing the financial impact on the company. These developments reflect the company’s ongoing efforts to advance its pipeline and the varied analyst perspectives on its financial outlook.
Korro Bio stock closed at $13.79, representing a change of +$0.080 (+0.58%). In after-hours trading, the stock was reported at $13.77, with a change of $0.000 (0.00%).
Key Points
- Director Jean Francois Formela sold 171,405 shares worth approximately $2.46 million under a Rule 10b5-1 plan.
- Korro Bio added KRRO-111 to its pipeline for AATD, while KRRO-121 remains on schedule for H2 2026 regulatory filing.
- Analyst views are mixed: Jones Trading upgraded to Buy with a $23 target, while H.C. Wainwright lowered its target to $15 but kept a Buy rating.
Market and Sector Impact
This insider activity and the associated pipeline updates impact the biotech and pharmaceutical sectors, particularly those focused on rare diseases and gene editing technologies. The mixed analyst ratings highlight the ongoing evaluation of clinical progress versus financial sustainability in the biotech market.
Risks and Uncertainties
- The stock's high volatility, as noted by InvestingPro Tips, presents a risk for investors tracking short-term price movements.
- The discrepancy in analyst price targets, ranging from $15 to $23, reflects uncertainty regarding the company's financial outlook despite the Buy ratings.
- The reliance on the successful regulatory filing of KRRO-121 in H2 2026 and the clinical potential of KRRO-111 introduces execution risk to the company's pipeline strategy.